Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

By P. Parren, P. Marx, A. Hessell, A. Luckay, J. Harouse, C. Cheng‐Mayer, John P. Moore, D. Burton. Journal of Virology, 2001

738 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies (2004, background): “Virus challenge studies in animal models indicate that protection may require much higher concentrations of antibody than that required to achieve, for example, an IC90 in a PBMC assay (44, 73, 74, 79, 107).”
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies (2005, background): “Neutralizing Abs are of particular interest because their presence at the time of intravenous, vaginal, and oral routes of live virus challenge has been shown to prevent AIDS virus infection in nonhuman primates (31, 65, 66, 69, 84, 105).”
Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies (2009, background): “Data from lentiviral animal models suggest that antibodies capable of neutralizing primary strains of HIV-1 may have the capacity to prevent HIV-1 infection (1, 28, 30, 35).”
Structural definition of a conserved neutralization epitope on HIV-1 gp120 (2007, positive): “In vivo , b12 can protect macaques against vaginal challenge from pathogenic simian–human immunodeficiency virus (SHIV) 28 .”